ABSTRACT

India stood top among countries worldwide that have been severely impacted by the COVID-19 pandemic. With a population of over 1.3 billion people, it was tough to keep the virus from spreading. Just months after recovering from the first wave, the second wave of infection erupted, causing the country's economy to suffer. Experience of facing the first and 2nd wave of covid-19 and the threat of Delta variant government decided that the only possible solution to fight against covid-19 is to vaccinate the people. COVAXIN created by Bharat Biotech in joined forces with the NIV (National Institute of Virology) of the ICMR (Indian Council of Medical Research) showed 78% efficiency against the COVID-19 virus and played a vital role in handling it. This review article aims to improve awareness among the people regarding COVAXIN along with the data supporting its performance. Keywords: COVID-19; COVAXIN; efficacy; clinical trials
Publication date: 01/08/2022

https://ijbpas.com/pdf/2022/August/MS_IJBPAS_2022_6333.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.8.6333